Natural Product (NP) Details
| General Information of the NP (ID: NP9147) | |||||
|---|---|---|---|---|---|
| Name |
Dihydroisotanshinone 1
|
||||
| Species Origin | Salvia trijuga ... | Click to Show/Hide | |||
| Salvia trijuga | |||||
| Disease | Colon cancer [ICD-11: 2B90] | Investigative | [1] | ||
| ADMET Property |
Absporption
Caco-2 Permeability
-4.459
MDCK Permeability
-4.421
PAMPA
+
HIA
+
Distribution
VDss
0.461
PPB
98.3%
BBB
- - -
Metabolism
CYP1A2 inhibitor
+++
CYP1A2 substrate
++
CYP2C19 inhibitor
+++
CYP2C19 substrate
- -
CYP2C9 inhibitor
++
CYP2C9 substrate
- - -
CYP2D6 inhibitor
- - -
CYP2D6 substrate
- - -
CYP3A4 inhibitor
+
CYP3A4 substrate
- - -
CYP2B6 inhibitor
+++
CYP2B6 substrate
- -
CYP2C8 inhibitor
+++
HLM Stability
+++
Excretion
CLplasma
4.589
T1/2
0.883
Toxicity
DILI
+++
Rat Oral Acute Toxicity
+
FDAMDD
+
Respiratory
-
Human Hepatotoxicity
+++
Ototoxicity
+
Drug-induced Nephrotoxicity
+++
Drug-induced Neurotoxicity
++
Hematotoxicity
+++
Genotoxicity
+++
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Ionizing radiation | Renal Insufficiency | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | MSH3 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | ||
| PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Dihydroisotanshinone I combined with radiation inhibits the migration ability of prostate cancer cells through DNA damage and CCL2 pathway. | |||||
